touchNEUROLOGY joins Prof James Galvin (University of Miami Miller School of Medicine, Miami, FL, USA) to discuss aducanumab for the treatment of Alzheimer’s disease, and what this recent accelerated approval might mean for future potential treatments.
1. Why has the recent FDA accelerated approval of aducanumab for Alzheimer’s disease been so controversial? (00:13-02:00)
2. Why did the EMERGE clinical study meet its primary endpoint, but the ENGAGE study did not? (02:00-04:21)
3. Which patients are most likely to benefit from aducanumab and in whom should it not be used? (04:21-05:13)
4. What are the consequences of this accelerated approval and how will this impact future research for Alzheimer’s disease? (05:13-08:38)
Disclosures: Prof Galvin has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 AAIC Annual Meeting.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
touchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Ivana Rosenzweig, Sleep and Breathing 2021: The Link Between Sleep Apnoea and Dementia
We were delighted to speak with Dr Ivana Rosenzweig (Sleep and Brain Plasticity Centre, King’s College London, London, UK) around her talk on the ‘Link between sleep apnoea and dementia: the neuroimaging perspective‘, which was presented at the virtual 2021 Sleep and Breathing Conference, 16-17 April, 2021. Questions What is known about the relationship between […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!